Beyond fibrinolysis: The role of plasminogen activator inhibitor-1 and vitronectin in vascular wound healing

Trends in Cardiovascular Medicine

Volumn 8, Issue 4, 1998, Pages 175-180

  Stefansson, Steingrimur ^a   Haudenschild, Christian C ^a   Lawrence, Daniel A ^a  

^a HOLLAND LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE INHIBITOR; UROKINASE; VITRONECTIN;

BLOOD VESSEL INJURY; CELL MIGRATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ENZYME INHIBITION; FIBRINOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEINASE INHIBITION; REVIEW; WOUND HEALING;

EID: 0032076752     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1050-1738(98)00003-6     Document Type: Review

References (57)

1. Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol. 70:1988;327-333.
2. Brooks PC, Stromblad S, Klemke Ret al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest. 96:1995;1815-1822.
3. Carmeliet P, Moons L, Herbert JMet al. Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. Circ Res. 81:1997;829-839.
4. Carmeliet P, Moons L, Lijnen Ret al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation. 96:1997;3180-3191.
5. Carmeliet P, Moons L, Ploplis V, Plow E, Collen D Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest. 99:1997;200-208.
6. 3 on vascular cells during wound repair. Am J Pathol. 148:1996;1407-1421.
7. Clyman RI, Mauray F, Kramer RH Beta 1 and beta 3 integrins have different roles in the adhesion and migration of vascular smooth muscle cells on extracellular matrix. Exp Cell Res. 200:1992;272-284.
8. Declerck PJ, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen D Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunoabsorbent assay. Blood. 71:1988;220-225.
9. Declerck PJ, De Mol M, Alessi MC, et al.: 1988b. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. J Biol Chem 263:15,454-15,461.
10. Deng G, Royle G, Seiffert D, Loskutoff DJ The PAI-1/vitronectin interaction: two cats in a bag. Thromb Haemost. 74:1995;66-70.
11. Deng G, Royle G, Wang S, Crain K, Loskutoff DJ: 1996a. Structural and functional analysis of the plasminogen activator inhibitor-1 binding motif in the somatomedin B domain of vitronectin. J Biol Chem 271: 12,716-12,723.
12. Deng G, Curriden SA, Wang S, Rosenberg S, Lostkutoff DJ Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release. J Cell Biol. 134:1996;1563-1573.
13. Ehrlich HJ, Gebbink RK, Preissner KTet al. Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix. J Cell Biol. 115:1991;1773-1781.
14. Fay WP, Shapiro AD, Shih JL, Schleef RR, Ginsburg D Complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med. 327:1992;1729-1733.
15. Fay WP, Eitzman DT, Shapiro AD, Madison EL, Ginsburg D Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1 dependent and independent mechanisms. Blood. 83:1994;351-356.
16. Fay WP, Parker AC, Condrey LR, Shapiro AD Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood. 90:1997;204-208.
17. Felsenfeld DP, Choquet D, Sheetz MP Ligand binding regulates the directed movement of beta 1 integrins on fibroblasts. Nature. 383:1996;438-440.
18. Gibbons GH, Dzau VJ Molecular therapies for vascular diseases. Science. 272:1996;689-693.
19. Hamsten A, Wiman B, de Faire U, Blombäck M Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 313:1985;1557-1563.
20. Holvoet P, Collen D Thrombosis and atherosclerosis. Curr Opin Lipidol. 8:1997;320-328.
21. Hoshiga M, Alpers CE, Smith LL, Giachelli CM, Schwartz SM Alpha-v beta-3 integrin expression in normal and atherosclerotic artery. Circ Res. 77:1995;1129-1135.
22. Hynes RO Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 69:1992;11-25.
23. Jang I-K, Gold HK, Ziskind AAet al. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. Circulation. 79:1989;920-928.
24. Kanse SM, Kost C, Wilhelm OG, Andreasen PA, Preissner KT The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res. 224:1996;344-353.
25. Kjoller L, Kanse SM, Kirkegaard Tet al. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res. 232:1997;420-429.
26. Larjava H, Salo T, Haapasalmi Ket al. Expression of integrins and basement membrane components by wound keratinocytes. J Clin Invest. 92:1993;1425-1435.
27. Lauffenburger DA Cell motility: making connections count. Nature. 383:1996;390-391.
28. Lauffenburger DA, Horwitz AF Cell migration: a physically integrated molecular process. Cell. 84:1996;359-369.
29. Lawrence DA The serpin-proteinase complex revealed. Nat Struct Biol. 4:1997;339-341.
30. Lawrence DA, Ginsburg D: 1995. Gene expression and function of plasminogen activator inhibitor-1. In Glas-Greenwalt P, ed. Fibrinolysis in Disease: Molecular and Hemovascular Aspects of Fibrinolysis. Boca Raton, FL, CRC Press, pp 21-29.
31. Lawrence DA, Berkenpas MB, Palaniappan S, Ginsburg D: 1994. Localization of vitronectin binding domain in plasminogen activator inhibitor-1. J Biol Chem 269: 15,223-15,228.
32. Lawrence DA, Ginsburg D, Day DE, et al.: 1995. Serpin-protease complexes are trapped as stable acyl-enzyme intermediates. J Biol Chem 270:25, 309-25,312.
33. Lawrence DA, Palaniappan S, Stefansson Set al. Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin: implications for the regulation of pericellular proteolysis. J Biol Chem. 272:1997;7676-7680.
34. Levi M, Biemond BJ, van Zonneveld A-J, ten Cate JW, Pannekoek H Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation. 85:1992;305-312.
35. Lindahl TL, Sigurdardóttir O, Wiman B Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb Haemost. 62:1989;748-751.
36. Loskutoff DJ PAI-1 inhibits neointimal formation after arterial injury in mice: a new target for controlling restenosis? Circulation. 96:1997;2772-2774.
37. Naski MC, Lawrence DA, Mosher DF, Podor TJ, Ginsburg D: 1993. Kinetics of inactivation of α-thrombin by plasminogen activator inhibitor-1: comparison of the effects of native and urea-treated forms of vitronectin. J Biol Chem 268:12,367-12,372.
38. Nikol S, Hofling B Regulation of smooth muscle cell proliferation and its possible role in preventing restenosis post-angioplasty. Wien Klin Wochenschr. 107:1995;379-389.
39. Palecek SP, Loftus JC, Ginsberg MH, Lauffenburger DA, Horwitz AF Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness. Nature. 385:1997;537-540.
40. Peterson CB Binding sites on native and multimeric vitronectin exhibit similar affinity for heparin: the influence of self-association and multivalence on ligand binding. Trends Cardiovasc Med. 8:1998;124-131.
41. Salomaa V, Stinson V, Kark JDet al. Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study: Atherosclerosis Risk in Communities Study. Circulation. 91:1995;284-290.
42. Schneiderman J, Sawdey MS, Keeton MRet al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA. 89:1992;6998-7002.
43. Seiffert D, Schleef RR Two functionally distinct pools of vitronectin (Vn) in the blood circulation: identification of a heparin-binding competent population of Vn within platelet alpha-granules. Blood. 88:1996;552-560.
44. Seiffert D, Smith JW: 1997. The cell adhesion domain in plasma vitronectin is cryptic. J Biol Chem 272:13,705-13,710.
45. Shore JD, Day DE, Francis-Chmura AMet al. A fluorescent probe study of plasminogen activator inhibitor-1: evidence for reactive center loop insertion and its role in the inhibitory mechanism. J Biol Chem. 270:1994;5395-5398.
46. 3 binding to vitronectin. Nature. 383:1996;441-443.
47. Stefansson S, Lawrence DA, Argraves WS Plasminogen activator inhibitor-1 (PAI1) and vitronectin promote the cellular clearance of thrombin by LDL-receptor related proteins 1 and 2. J Biol Chem. 271:1996;8215-8220.
48. Stefansson S, Muhammad S, Cheng X-Fet al. Plasminogen activator inhibitor-1 contains a cryptic high affinity binding site for the low density lipoprotein receptor-related protein. J Biol Chem. 273:1998;6358-6366.
49. Stein P, Chothia C Serpin tertiary structure transformation. Mol Biol. 221:1991;615-621.
50. 3 integrins are upregulated after vascular injury and modulate thrombospondin- and thrombin-induced proliferation of cultured smooth muscle cells. Circulation. 94:1998;907-915.
51. Tomasini BR, Mosher DF Vitronectin. Prog Hemost Thromb. 10:1991;269-305.
52. van Aken BE, Seiffert D, Thinnes T, Loskutoff DJ Localization of vitronectin in the normal and atherosclerotic human vessel wall. Histochem Cell Biol. 107:1997;313-320.
53. Wei Y, Waltz DA, Rao N, et al.: 1994. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269:32,380-32,388.
54. Wei Y, Lukashev M, Simon DIet al. Regulation of integrin function by the urokinase receptor. Science. 273:1996;1551-1555.
55. Wilczynska M, Fa M, Karolin Jet al. New structural insights into native serpin-protease complexes reveal the inhibitory mechanism of serpins. Nat Struct Biol. 4:1997;354-357.
56. Winkles JA, Friesel R, Alberts GF, Janat MF, Liau G Elevated expression of basic fibroblast growth factor in an immortalized rabbit smooth muscle cell line. Am J Pathol. 143:1993;518-527.
57. Zhuang P, Chen AI, Peterson CB Native and multimeric vitronectin exhibit similar affinity for heparin: differences in heparin binding properties induced upon denaturation are due to self-association into a multivalent form. J Biol Chem. 272:1997;6858-6867.